Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Nuvalent, Inc. (NUVL) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,398.37 | 855.99 | 203.34 | 29.37 | 35.16 | 0.00 | 19.5620 | -0.42 | -0.9710 | -22.7434 | -0.08 | -0.08 | 7.0236 | - - | ||
| Maximum | - - | - - | - - | 445,233.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
| United Therapeutics Corporation UTHR | 369.80 | 5.47 1.50% | 68 vs. 363 | 16,509.00 | 677.00 | 306.00 | 338.00 | 6,333.00 | 6.5200 | 8.7477 | 0.0000 | 0.8924 | 0.4524 | 0.0574 | 0.0472 | 3.5035 | 44.00 | ||
| Nuvalent, Inc. NUVL | 93.38 | 2.21 2.42% | 111 vs. 533 | 6,634.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
| DICE Therapeutics, Inc. DICE | 47.55 | 0.03 0.06% | 4,332 vs. 1,753 | 2,270.00 | 0.00 | -34.00 | -30.00 | -248.00 | -0.7400 | -15.7831 | 0.0000 | 0.0000 | 0.0000 | -0.0671 | -0.0632 | 25.6858 | 47.00 | ||
| Vaxcyte, Inc. PCVX | 90.10 | 4.14 4.82% | 812 vs. 1,214 | 11,229.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.0000 | 0.0000 | 0.0000 | -0.0479 | -0.0454 | 17.2498 | 124.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.